{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:06:48Z","timestamp":1783768008796,"version":"3.55.0"},"reference-count":98,"publisher":"Akademiai Kiado Zrt.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Magyar Onkol\u00f3gia"],"published-print":{"date-parts":[[2009,12,1]]},"DOI":"10.1556\/monkol.53.2009.4.6","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T02:02:37Z","timestamp":1263434557000},"page":"369-375","source":"Crossref","is-referenced-by-count":1,"title":["Lapatinib \u2013 kezel\u00e9si lehet\u0151s\u00e9g trastuzumab-rezisztens eml\u0151r\u00e1kban","Lapatinib \u2013 treatment-option in trastuzumab-resistant breast cancer"],"prefix":"10.1556","volume":"53","author":[{"given":"B\u00e9la","family":"Pik\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism","volume":"94","author":"Arnould L","year":"2006","journal-title":"Br J Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/bcr574","article-title":"Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer (commentary)","volume":"5","author":"Arteaga CL","year":"2003","journal-title":"Breast Cancer Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Beano A","year":"2008","journal-title":"J Translation Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr55","article-title":"Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer","volume":"2","author":"Biscardi JS","year":"2000","journal-title":"Breast Cancer Res"},{"key":"5","first-page":"3006","article-title":"A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer","volume":"22","author":"Blackwell KL","year":"2004","journal-title":"J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Ed.)"},{"key":"6","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinase, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"Burris HA","year":"2005","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","article-title":"A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer","volume":"19","author":"Burstein HJ","year":"2008","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron D","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3816\/CBC.2002.n.028","article-title":"Resistance to trastuzumab: a necessary evil or a temporal challenge","volume":"3","author":"Cardoso F","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10","unstructured":"10. Carlson RW, Craig AD, Anderson BO, et al. Breast Cancer \u2013 National Comprehensive Cancer Network \u2013 Practice Guidelines in Oncology, v.1. 2009 <a href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf\">http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf<\/a>"},{"key":"11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4143\/crt.2006.38.4.198","article-title":"Lapatinib \u2013 Overview and current role in metastatic breast cancer","volume":"38","author":"Chan A","year":"2006","journal-title":"Cancer Res Treat"},{"key":"12","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2007.11.1765","article-title":"Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies","volume":"25","author":"Chu QS","year":"2007","journal-title":"J Clin Oncol"},{"key":"13","unstructured":"13. Clemens M, Kaufman B, Mackey JR, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study. 2007 Breast Cancer Symposium, Abstr 231, 2007 <a href=\"http:\/\/www.asco.org\/ASCO\/Abstracts+&+Virtual+Meeting\/Abstracts?&vmview=abst_detail_view&confID=52&abstractID=40220\">http:\/\/www.asco.org\/ASCO\/Abstracts+&+Virtual+Meeting\/Abstracts?&vmview=abst_detail_view&confID=52&abstractID=40220<\/a>"},{"key":"14","first-page":"21","article-title":"Targeted treatment of advanced and metastatic breast cancer with lapatinib","volume":"1","author":"Corkery B","year":"2008","journal-title":"OncoTargets Ther"},{"key":"15","first-page":"23","article-title":"HER2 immunhisztok\u00e9miai vizsg\u00e1latok min\u0151s\u00e9gellen\u0151rz\u00e9se \u2013 Egy magyarorsz\u00e1gi k\u00f6rvizsg\u00e1lat eredm\u00e9nyei","volume":"51","author":"Cserni G","year":"2007","journal-title":"Magyar Onkol\u00f3gia"},{"key":"16","volume-title":"Onkofarmakol\u00f3gia","author":"Dank M","year":"2005"},{"key":"17","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/annonc\/mdi901","article-title":"Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology","volume":"16","author":"Laurentiis M","year":"2005","journal-title":"Ann Oncol"},{"key":"18","first-page":"10","article-title":"Looking beyond trastuzumab: new targeted therapies in breast cancer","volume":"8","author":"Cosimo S","year":"2006","journal-title":"Breast International Group (BIG) Newsletter"},{"key":"19","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Leo A","year":"2008","journal-title":"J Clin Oncol"},{"key":"20","unstructured":"20. Dobozy E. Az Erbitux b\u0151rt\u00fcnetei \u00e9s kezel\u00e9s\u00fck (el\u0151ad\u00e1s). \u201eA fejnyak tumoros betegek Erbitux + sug\u00e1rter\u00e1pia kezel\u00e9se kapcs\u00e1n felmer\u00fcl\u0151 aktu\u00e1lis k\u00e9rd\u00e9sek\u201d Szimp\u00f3zium, Budapest, 2009"},{"key":"21","unstructured":"21. Eaby B. Nursing management of patients receiving EGFR inhibitors \u2013 cancer resources, nurses\u2019 notes, nursing continuing education, continuing education modules. <a href=\"http:\/\/www.oncolink.com\/resources\/article.cfm?c=16&s=59&ss=224&id=961\">http:\/\/www.oncolink.com\/resources\/article.cfm?c=16&s=59&ss=224&id=961<\/a>"},{"key":"22","first-page":"536","article-title":"A daganatok gy\u00f3gyszeres kezel\u00e9s\u00e9nek \u00faj ter\u00fclete: a c\u00e9lzott molekul\u00e1ris ter\u00e1pia","volume":"166","author":"Eckhardt S","year":"2005","journal-title":"Magyar Tudom\u00e1ny"},{"key":"23","unstructured":"23. Egerv\u00e1ri K. Az eml\u0151r\u00e1k HER2 diagnosztik\u00e1j\u00e1nak aktu\u00e1lis k\u00e9rd\u00e9sei (egyetemi doktori \u00e9rtekez\u00e9s). DEOEC Patol\u00f3giai Int\u00e9zet, Debrecen, 2008 <a href=\"http:\/\/www.ganymedes.lib.unideb.hu:8080\/...\/Egervari_Kristof_tezis_magyar.pdf\">http:\/\/www.ganymedes.lib.unideb.hu:8080\/...\/Egervari_Kristof_tezis_magyar.pdf<\/a>"},{"key":"24","volume-title":"Onkofarmakol\u00f3gia","author":"Egyed K","year":"2005"},{"key":"25","unstructured":"25. EMEA (European Medicines Agency). Herceptin alkalmaz\u00e1si el\u0151\u00edr\u00e1s <a href=\"http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Herceptin\/H-278-PI-hu.pdf\">http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Herceptin\/H-278-PI-hu.pdf<\/a>"},{"key":"26","unstructured":"26. EMEA (European Medicines Agency). Tyverb alkalmaz\u00e1si el\u0151\u00edr\u00e1s <a href=\"http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/tyverb\/H-795-PI-hu.pdf\">http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/tyverb\/H-795-PI-hu.pdf<\/a>"},{"key":"27","unstructured":"27. EMEA (European Medicines Agency). Xeloda alkalmaz\u00e1si el\u0151\u00edr\u00e1s <a href=\"http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Xeloda\/H-316-PI-hu.pdf\">http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Xeloda\/H-316-PI-hu.pdf<\/a>"},{"key":"28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","article-title":"Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer","volume":"20","author":"Esteva FJ","year":"2002","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1359-6349(04)90842-7","article-title":"Trastuzumab (Herceptin) plus Taxotere versus Taxotere alone as first line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial","volume":"2","author":"Extra JM","year":"2004","journal-title":"Eur J Cancer"},{"key":"30","volume-title":"A komplex onkodiagnosztika \u00e9s onkoter\u00e1pia ir\u00e1nyelvei","author":"Fodor J","year":"2008"},{"key":"31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1023\/A:1013184301155","article-title":"Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer","volume":"12","author":"Fountzilas G","year":"2001","journal-title":"Ann Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer CE","year":"2006","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2007.15.7404","article-title":"The \u201cother\u201d signaling of trastuzumab: antibodies are immunocompetent drugs","volume":"26","author":"Gianni L","year":"2008","journal-title":"J Clin Oncol"},{"key":"34","unstructured":"34. Gilde K. Az anti-EGFR ter\u00e1pia dermatol\u00f3giai vonatkoz\u00e1sai. \u201eAmgenius\u201d Tudom\u00e1nyos Szimp\u00f3zium, Visegr\u00e1d, 2009"},{"key":"35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.COT.0000288890.48242.32","article-title":"Exemestane & trastuzumab found cost-effective adjuvant treatments, models show","volume":"29","author":"Hogan M","year":"2007","journal-title":"Oncology Times"},{"key":"36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/bcr48","article-title":"Tyrosine kinase signaling in breast cancer","volume":"2","author":"Hynes NE","year":"2000","journal-title":"Breast Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","article-title":"Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization","volume":"10","author":"Isola J","year":"2004","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2325\/jbcs.971","article-title":"Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer","volume":"14","author":"Ito Y","year":"2007","journal-title":"Breast Cancer"},{"key":"39","volume-title":"Onkofarmakol\u00f3gia","author":"Jeney A","year":"2005"},{"key":"40","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","article-title":"Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer","volume":"42","author":"Johnston S","year":"2006","journal-title":"Drugs Today"},{"key":"41","first-page":"138","article-title":"A HER-2 status klinikai jelent\u0151s\u00e9ge eml\u0151r\u00e1kban","volume":"11","author":"Kah\u00e1n Zs","year":"2001","journal-title":"LAM"},{"key":"42","first-page":"739","article-title":"Eml\u0151r\u00e1k az onkol\u00f3giai gyakorlatban \u2013 A megel\u0151z\u00e9st\u0151l a gondoz\u00e1sig","volume":"16","author":"Kah\u00e1n Zs","year":"2006","journal-title":"LAM"},{"key":"43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/bcr54","article-title":"Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates","volume":"2","author":"Kairouz R","year":"2000","journal-title":"Breast Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HCO.0b013e32801129eb","article-title":"Drug-induced long QT and torsade de pointes: Recent advances","volume":"22","author":"Kannankeril PJ","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kaplan EH, Jones CM, Berger MS. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. J Clin Oncol, Proc Am Soc Clin Oncol 22: Abstr 981, 2003","DOI":"10.1200\/jco.2004.22.14_suppl.3006"},{"key":"46","volume-title":"A feln\u0151ttkori daganatos betegs\u00e9gek gy\u00f3gyszeres kezel\u00e9se","author":"Kerpel-Fronius S","year":"1998"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Koch KM, Lee D, Mangum S, et al. Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer subjects. Eur J Cancer 1(Suppl 5): poster 559, 2003","DOI":"10.1016\/S1359-6349(03)90591-X"},{"key":"48","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny GE","year":"2006","journal-title":"Cancer Res"},{"key":"49","volume-title":"Molekul\u00e1ris onkol\u00f3gia","author":"Kopper L","year":"2007"},{"key":"50","first-page":"990","article-title":"A patol\u00f3giai vizsg\u00e1latok szerepe a \u201ec\u00e9lzott\u201d ter\u00e1pia kialak\u00edt\u00e1s\u00e1ban, hat\u00e1s\u00e1nak monitoroz\u00e1s\u00e1ban \u00e9s a betegs\u00e9gek kimenetel\u00e9nek el\u0151rejelz\u00e9s\u00e9ben","volume":"167","author":"Kopper L","year":"2007","journal-title":"Magyar Tudom\u00e1ny"},{"key":"51","volume-title":"Molekul\u00e1ris Onkol\u00f3gia","author":"Kopper L","year":"2007"},{"key":"52","first-page":"565","article-title":"Molekul\u00e1risan c\u00e9lzott biol\u00f3giai ter\u00e1pia a szolid tumorok kezel\u00e9s\u00e9ben I. Eml\u0151r\u00e1k \u00e9s colorectalis r\u00e1k","volume":"17","author":"L\u00e1ng I","year":"2007","journal-title":"LAM"},{"key":"53","first-page":"195","article-title":"Lehet\u0151s\u00e9gek \u00e9s eredm\u00e9nyek a Taxol\u00ae-Herceptin\u00ae kombin\u00e1ci\u00f3 alkalmaz\u00e1s\u00e1val","volume":"46","author":"L\u00e1ng I","year":"2002","journal-title":"Magyar Onkol\u00f3gia"},{"key":"54","first-page":"503","article-title":"Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer","volume":"24","author":"Lin NU","year":"2006","journal-title":"J Clin Oncol, ASCO Annual Meeting Proceedings Part I."},{"key":"55","first-page":"1012","article-title":"EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)","volume":"25","author":"Lin NU","year":"2007","journal-title":"ASCO Annu Meet Proc J Clin Oncol"},{"key":"56","unstructured":"56. Lin NU, Paul D, Dieras V, et al. Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer: an updated analysis from EGF105084, Abstr 6076 <a href=\"http:\/\/www.posters2view.com\/sabcs07\/viewp.php?nu=6076\">http:\/\/www.posters2view.com\/sabcs07\/viewp.php?nu=6076<\/a>"},{"key":"57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr919","article-title":"Small molecule tyrosine kinase inhibitors \u2013 New targets for therapy in breast cancer","volume":"6","author":"Lin NU","year":"2004","journal-title":"Breast Cancer Res"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Liu Q, Madabushi R, Garnett C, et al. Experience in QT evaluation of oncology drug products since ICH E14 guidance. J Clin Oncol 26(Suppl): Abstr 2554, 2008","DOI":"10.1200\/jco.2008.26.15_suppl.2554"},{"key":"59","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group","volume":"23","author":"Marty M","year":"2005","journal-title":"J Clin Oncol"},{"key":"60","first-page":"347","article-title":"NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer","volume":"8","author":"Molina MA","year":"2002","journal-title":"Clin Cancer Res"},{"key":"61","unstructured":"61. Morrow PK. Targeted therapy in breast cancer. In: Metastatic Breast Cancer Network 2nd Annual Meeting, Houston, 2007 <a href=\"http:\/\/www.mbcnetwork.org\/uploads\/TARGETED%20RX%20BR%20CA%202007.pdf\">http:\/\/www.mbcnetwork.org\/uploads\/TARGETED%20RX%20BR%20CA%202007.pdf<\/a>"},{"key":"62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1634\/theoncologist.11-10-1047","article-title":"Lapatinib: Current status and future directions in breast cancer","volume":"11","author":"Moy B","year":"2006","journal-title":"Oncologist"},{"key":"63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanism of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta R","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"64","first-page":"665","article-title":"A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer","volume":"3","author":"Nelson MH","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"65","unstructured":"65. Nelson R. Mechanism explains different cardiotoxicity of trastuzumab and lapatinib. June 14, 2007 <a href=\"http:\/\/www.theheart.org\/article\/797013.do\">http:\/\/www.theheart.org\/article\/797013.do<\/a>"},{"key":"66","first-page":"103","article-title":"Paradigmav\u00e1lt\u00e1s a daganatok patol\u00f3giai diagnosztik\u00e1j\u00e1ban: molekul\u00e1ris alap\u00fa differenci\u00e1ldiagnosztika, prognosztikus \u00e9s predikt\u00edv patol\u00f3gia","volume":"51","author":"Orosz Zs","year":"2007","journal-title":"Magyar Onkol\u00f3gia"},{"key":"67","first-page":"82","article-title":"Az immunhisztok\u00e9mia szerepe a daganatter\u00e1pi\u00e1s c\u00e9lpontok azonos\u00edt\u00e1s\u00e1ban","volume":"28","author":"Orosz Zs","year":"2004","journal-title":"Biok\u00e9mia"},{"key":"68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jjco\/hyg093","article-title":"Measuring response in solid tumors: Comparison of RECIST and WHO Response Criteria","volume":"33","author":"Park JO","year":"2003","journal-title":"Jpn J Clin Oncol"},{"key":"69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3816\/CBC.2008.n.047","article-title":"Unraveling the biologic and clinical complexities of HER2","volume":"8","author":"Park JW","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1526-8209(11)70897-7","article-title":"Lapatinib, a dual ErbB-1\/ErbB-2 kinase inhibitor, in the treatment of HER2-overexpressing local advanced and metastatic breast cancer","volume":"7","author":"Peck SR","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez EA","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1556\/MOnkol.53.2009.2.5","article-title":"Panitumumab alkalmaz\u00e1sa az \u00e1tt\u00e9tes vastag- \u00e9s v\u00e9gb\u00e9lr\u00e1kos betegek kezel\u00e9s\u00e9ben","volume":"53","author":"Pik\u00f3 B","year":"2009","journal-title":"Magyar Onkol\u00f3gia"},{"key":"73","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/bcr52","article-title":"Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification","volume":"2","author":"Prenzel N","year":"2000","journal-title":"Breast Cancer Res"},{"key":"74","unstructured":"74. Rapi K. Orsz\u00e1gos Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si P\u00e9nzt\u00e1r F\u0151igazgat\u00f3 Helyettes k\u00f6rlevele valamennyi onkol\u00f3giai centrum vezet\u0151j\u00e9nek a Tyverb m\u00e9lt\u00e1nyoss\u00e1gi k\u00e9relmekkel kapcsolatban. Nyt. sz\u00e1m: 97-125\/08. 2008. szeptember 9. <a href=\"http:\/\/www.oep.hu\/pls\/portal\/docs\/PAGE\/SZAKMA\/OEPHUSZAK_EUSZOLG\/GYOGYSZER\/EGYEDI%20T%C3%81MOGAT%C3%81SOK\/125F%C5%90IG.K%C3%96RLEV%C3%89L%20VALAMENNYI%20ONK.CENTRUMNAKTYVERB.PDF\">http:\/\/www.oep.hu\/pls\/portal\/docs\/PAGE\/SZAKMA\/OEPHUSZAK_EUSZOLG\/GYOGYSZER\/EGYEDI%20T%C3%81MOGAT%C3%81SOK\/125F%C5%90IG.K%C3%96RLEV%C3%89L%20VALAMENNYI%20ONK.CENTRUMNAKTYVERB.PDF<\/a>"},{"key":"75","first-page":"7196","article-title":"The characterization of novel, dual ErbB-2\/EGFR, tyrosine kinase inhibitors: potential therapy for cancer","volume":"61","author":"Rusnak DW","year":"2001","journal-title":"Cancer Res"},{"key":"76","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor ErbB2 tyrosine kinase inhibitor GW2016 on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak DW","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"77","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","article-title":"FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2","volume":"13","author":"Ryan Q","year":"2008","journal-title":"Oncologist"},{"key":"78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1078-0432.CCR-05-1807","article-title":"p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer","volume":"12","author":"Saez R","year":"2006","journal-title":"Clin Cancer Res"},{"key":"79","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti M","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"80","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert S","year":"2005","journal-title":"Ann Oncol"},{"key":"81","first-page":"3070","article-title":"Phase I clinical, biology, and pharmacokinetic study of the combination of GW572016 and capecitabine in patients with advanced solid tumors","volume":"22","author":"Schwartz G","year":"2004","journal-title":"ASCO Annu Meet Proc, J Clin Oncol"},{"key":"82","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","journal-title":"N Engl J Med"},{"key":"83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER2\/neu oncogene","volume":"235","author":"Slamon DJ","year":"1987","journal-title":"Science"},{"key":"84","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0959-8049(02)00182-X","article-title":"Measuring the clinical response. What does it mean","volume":"38","author":"Therasse P","year":"2002","journal-title":"Eur J Cancer"},{"key":"85","first-page":"14","article-title":"Fontolva halad\u00f3 klinikai onkol\u00f3gia \u2013 Gondolatok az ASCO 42. konferenci\u00e1ja kapcs\u00e1n","volume":"4","author":"T\u00edm\u00e1r J","year":"2006","journal-title":"Medical Tribune"},{"key":"86","first-page":"16","article-title":"Kis l\u00e9p\u00e9sek az onkol\u00f3gia, nagy l\u00e9p\u00e9sek a beteg emberek sz\u00e1m\u00e1ra \u2013 ASCO 2007, Chicago","volume":"5","author":"T\u00edm\u00e1r J","year":"2007","journal-title":"Medical Tribune"},{"key":"87","first-page":"39","article-title":"HER2-expresszi\u00f3 eml\u0151r\u00e1kban","volume":"44","author":"T\u00f3th J","year":"2000","journal-title":"Magyar Onkol\u00f3gia"},{"key":"88","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2325\/jbcs.13.374","article-title":"A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab","volume":"13","author":"Tsutani Y","year":"2006","journal-title":"Breast Cancer"},{"key":"89","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neu-regulin and epidermal growth factor","volume":"16","author":"Tzahar E","year":"1996","journal-title":"Mol Cell Biol"},{"key":"90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000101528","article-title":"Therapy with lapatinib: Current status in women with advanced breast cancer","volume":"2","author":"Untch M","year":"2007","journal-title":"Breast Care"},{"key":"91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2559.2003.01598.x","article-title":"Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study","volume":"42","author":"Vincent-Salomon A","year":"2003","journal-title":"Histopathology"},{"key":"92","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel CL","year":"2002","journal-title":"J Clin Oncol"},{"key":"93","unstructured":"93. Without Author. Common Toxicity Criteria \u2013 US Food and Drug Administration \u2013 Center for Drug Evaluation and Research \u2013 Oncology Tools \u2013 NCI (National Cancer Institute) <a href=\"http:\/\/www.fda.gov\/cder\/cancer\/toxicityframe.htm\">http:\/\/www.fda.gov\/cder\/cancer\/toxicityframe.htm<\/a>"},{"key":"94","unstructured":"94. Without Author. Cutaneous effects. Skin rash associated with targeted therapy, last modified on 10\/25\/2006 <a href=\"http:\/\/www.managecrc.com\/html\/side-effect-rash.asp\">http:\/\/www.managecrc.com\/html\/side-effect-rash.asp<\/a>"},{"key":"95","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/bcr613","article-title":"Structure of HER receptors and intracellular localisation of downstream effector elements gives insight into mechanism of tumour growth promotion","volume":"5","author":"Witton CJ","year":"2003","journal-title":"Breast Cancer Res"},{"key":"96","unstructured":"96. Wong ZW, Isaacs C, Harris L, et al. A phase II trial of letrozole and trastuzumab for ER and\/or PgR and HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol, Abstr 444, 2003"},{"key":"97","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib), relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood ER","year":"2004","journal-title":"Cancer Res"},{"key":"98","first-page":"513","article-title":"Lapatinib in the treatment of breast cancer","volume":"1","author":"Yamauchi H","year":"2009","journal-title":"Clin Med Ther"}],"container-title":["Magyar Onkol\u00f3gia"],"original-title":[],"link":[{"URL":"https:\/\/akademiai.com\/doi\/pdf\/10.1556\/monkol.53.2009.4.6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:56:46Z","timestamp":1590141406000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/monkol.53.2009.4.6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12,1]]}},"alternative-id":["24622770T583UJ41"],"URL":"https:\/\/doi.org\/10.1556\/monkol.53.2009.4.6","relation":{},"ISSN":["0025-0244","2060-0399"],"issn-type":[{"value":"0025-0244","type":"print"},{"value":"2060-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,1]]}}}